白云山(600332)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600332 白云山

已收盘 11-19 15:00:00

{"stockData":{"symbol":"600332","market":"SH","secType":"STK","nameCN":"白云山","latestPrice":28.74,"timestamp":1731999601000,"preClose":28.59,"halted":0,"volume":6185439,"delay":0,"floatShares":1406000000,"shares":1626000000,"eps":2.1057,"marketStatus":"已收盘","marketStatusCode":5,"change":0.15,"latestTime":"11-19 15:00:00","open":28.68,"high":28.93,"low":28.39,"amount":177000000,"amplitude":0.0189,"askPrice":28.75,"askSize":71,"bidPrice":28.74,"bidSize":601,"shortable":0,"etf":0,"ttmEps":2.1057,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732066200000},"adr":0,"adjPreClose":28.59,"symbolType":"stock","openAndCloseTimeList":[[1731979800000,1731987000000],[1731992400000,1731999600000]],"highLimit":31.45,"lowLimit":25.73,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1625790949,"pbRate":1.29,"roa":"--","roe":"8.81%","epsLYR":2.495,"committee":0.550429,"marketValue":46725000000,"floatMarketCap":40405000000,"peRate":13.648668,"changeRate":0.0052,"turnoverRate":0.0044,"status":0},"requestUrl":"/m/hq/s/600332/tweets","defaultTab":"tweets","newsList":[{"id":"2484695405","title":"净利润持续下滑，白云山面临业绩与合规双重压力","url":"https://stock-news.laohu8.com/highlight/detail?id=2484695405","media":"酒业内参","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484695405?lang=zh_cn&edition=full","pubTime":"2024-11-19 11:28","pubTimestamp":1731986922,"startTime":"0","endTime":"0","summary":"不仅如此，在2023年第四季度，白云山已经出现了净利润下滑的现象，该季度白云山实现归属净利润2.644亿元，同比大幅下滑46.27%。2024年下半年以来，白云山原董事长李楚源和董事张春波相继被监管部门带走调查。白云山对此回应称，由于康业元未尽股东义务，且双方在金戈的研发、生产和经营过程中的贡献不同，应合理分配收益。而根据2024年中报，白云山与其合作伙伴关于金戈药品的销售利益分配仍未达成一致意见，双方的争执或仍将继续。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119112845abce110e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119112845abce110e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600332"],"gpt_icon":0},{"id":"2484927625","title":"白云山子公司新增冻干粉针剂等生产线","url":"https://stock-news.laohu8.com/highlight/detail?id=2484927625","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484927625?lang=zh_cn&edition=full","pubTime":"2024-11-18 19:26","pubTimestamp":1731929160,"startTime":"0","endTime":"0","summary":"白云山发布关于子公司《药品生产许可证》变更的公告。全资子公司明兴药业近期获得广东省药品监督管理局核准签发的《药品生产许可证》，同意其新增生产车间、生产线和生产范围，并通过药品生产质量管理规范符合性检查。根据公告，明兴药业在多个生产地址新增了小容量注射剂、小容量注射剂和冻干粉针剂的生产线。2024年前三季度，白云山实现收入590.60亿元，归母净利润31.59亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118193347abcc602c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118193347abcc602c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0096","BK0012","BK0028","BK0183","BK0239","BK0097","BK0175","BK0188","600332","BK0196","BK0070"],"gpt_icon":0},{"id":"2484964020","title":"白云山(00874)附属明兴药业收到广东省药品监督管理局核准签发的《药品生产许可证》","url":"https://stock-news.laohu8.com/highlight/detail?id=2484964020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484964020?lang=zh_cn&edition=full","pubTime":"2024-11-18 19:05","pubTimestamp":1731927941,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)发布公告，近日，该公司全资子公司广州白云山明兴制药有限公司(以下简称“明兴药业”)收到广东省药品监督管理局核准签发的《药品生产许可证》，同意明兴药业新增生产车间、生产线和生产范围，并通过药品生产质量管理规范符合性检查。本次明兴药业新增生产车间、生产线和生产范围，并通过药品生产质量管理规范符合性检查，有利于其优化产能，提升智能化、数字化、绿色化水平，继续保持稳定的生产能力，满足市场需求。本次获得《药品生产许可证》，对公司当期业绩无重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212428.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK0096","BK0028","600332","BK0097","BK0196","BK1606","BK1191","BK1521","00874","BK1197","BK0188","BK0239","BK0012","BK0175","BK1515","BK0183"],"gpt_icon":0},{"id":"2484614986","title":"白云山(00874)出现大手买入76万股，成交价$18.28，涉资1.389千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2484614986","media":"阿斯达克财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484614986?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:29","pubTimestamp":1731914940,"startTime":"0","endTime":"0","summary":"[大手成交]白云山(00874)在下午03:29出现大手买入，成交量为76万，成交价为港币$18.28，涉资1.389千万。至目前为止，股价跌0.111%，今日最高价为$18.38，而最低价为$18.0，总成交量为223.82万股，总成交金额港币$4.075千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2411187817/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","BK0012","BK1606","BK0175","BK0188","BK0028","BK0096","BK1191","600332","BK0097","BK0196","BK1521","BK0070","BK0239","00874","BK1197","BK0183"],"gpt_icon":0},{"id":"2484113526","title":"白云山11月18日主力资金流出2205万元 连续7日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2484113526","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484113526?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:18","pubTimestamp":1731914330,"startTime":"0","endTime":"0","summary":"11月18日, 白云山股价跌1.04%，报收28.59元，成交金额3.03亿元，换手率0.74%，振幅2.98%，量比0.88。白云山今日主力资金净流出2205万元，连续7日净流出，上一交易日主力净流出1184万元，今日环比增加86.23%。该股近5个交易日下跌2.69%，主力资金累计净流出8598万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出2.05亿元，其中净流出天数为16日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118152547abcba01a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118152547abcba01a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0183","BK0188","BK0097","BK0012","BK0028","BK0070","BK0096","BK0239","BK0175","BK0196","600332"],"gpt_icon":0},{"id":"2483592903","title":"白云山净利润“凉凉”：王老吉、金戈双拳难敌市场冲击，理财借款两不误？","url":"https://stock-news.laohu8.com/highlight/detail?id=2483592903","media":"酒业内参","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483592903?lang=zh_cn&edition=full","pubTime":"2024-11-16 18:17","pubTimestamp":1731752220,"startTime":"0","endTime":"0","summary":"三季报显示，白云山归母净利润为31.59亿元，同比下降16.68%。今年以来，白云山的归母净利润已经连续两个季度下滑了。对于净利润下滑如此严重，白云山给出的理由则是：受宏观经济波动、市场竞争及行业政策等因素影响，本公司下属子公司销售收入较去年同期减少。净利润大幅下滑的同时，白云山的各项业务毛利率出现不同程度的下滑。不仅如此，白云山另一款拳头产品，有着“国产伟哥”之称的金戈也正在遭遇冲击。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116184241abc7195c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116184241abc7195c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600332"],"gpt_icon":0},{"id":"2483008466","title":"Norges Bank减持白云山(00874)54万股 每股作价约19.12港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483008466","media":"智通财经网","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483008466?lang=zh_cn&edition=full","pubTime":"2024-11-13 18:41","pubTimestamp":1731494460,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，11月8日，Norges Bank减持白云山(00874)54万股，每股作价19.1161港元，总金额约为1032.27万港元。减持后最新持股数目为1715.3万股，最新持股比例为7.80%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-13/doc-incvxpfh7952949.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-13/doc-incvxpfh7952949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0096","BK1197","BK0196","BK0175","BK0028","BK1515","BK0183","BK1606","BK1521","BK1191","BK0239","BK0070","BK0097","600332","BK0188","00874","BK0012"],"gpt_icon":0},{"id":"2483094920","title":"南向资金11月12日净买入白云山52.60万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2483094920","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483094920?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:30","pubTimestamp":1731461410,"startTime":"0","endTime":"0","summary":"11月12日, 南向资金增持白云山52.60万股，连续5日增持。截止当日收盘，港股通共持有白云山11878.46万股，占流通股54.00%。港股通增持金额前五个股分别为中芯国际、建设银行、中升控股、安踏体育、中国神华。白云山近5个交易日上涨1.07%，港股通累计增持189.20万股；近20个交易日上涨0.42%，港股通累计增持783.20万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113093045abbb7e4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113093045abbb7e4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1197","BK1521","00874","BK1606","BK1191","600332"],"gpt_icon":0},{"id":"2482774076","title":"白云山：关于该事项的说明详见本公司2023年年度报告的有关内容","url":"https://stock-news.laohu8.com/highlight/detail?id=2482774076","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482774076?lang=zh_cn&edition=full","pubTime":"2024-11-12 19:00","pubTimestamp":1731409234,"startTime":"0","endTime":"0","summary":"证券之星消息，白云山11月12日在投资者关系平台上答复投资者关心的问题。关于该事项的说明详见本公司2023年年度报告的有关内容。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111200031013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["00874","BK0096","BK0183","BK0028","BK1197","BK0196","BK0188","BK1191","BK0097","BK1521","BK0012","BK1515","BK0070","BK0175","BK0239","600332","BK1606"],"gpt_icon":0},{"id":"2481926785","title":"中药板块前三季度业绩承压，白云山、太极集团净利大幅下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2481926785","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481926785?lang=zh_cn&edition=full","pubTime":"2024-11-07 16:15","pubTimestamp":1730967308,"startTime":"0","endTime":"0","summary":"报告期内，白云山、健民集团、太极集团等多家中药龙头企业净利润下滑，尤其是第三季度降幅较大。今年前三季度，白云山实现营收590.6亿元，同比微增1.5%；归属于上市公司股东的净利润31.59亿元，同比下滑16.68%，增收不增利。其中第三季度营收下滑8.83%，归母净利润同比大幅下滑49.46%。其中，第三季度归母净利润同比大幅下滑73.82%，主要是因为销售收入同比下滑所致。中药材涨价，也对太极集团造成了影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107161831a21fc2b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107161831a21fc2b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0183","BK0096","BK0028","BK0196","BK0188","600129","BK0097","BK0012","BK0070","BK0175","BK0239","BK0113","600332"],"gpt_icon":0},{"id":"2481605338","title":"Norges Bank减持白云山(00874)80.8万股 每股作价约18.36港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481605338","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481605338?lang=zh_cn&edition=full","pubTime":"2024-11-06 20:24","pubTimestamp":1730895898,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，11月1日，Norges Bank减持白云山(00874)80.8万股，每股作价18.3615港元，总金额约为1483.6092万港元。减持后最新持股数目为1975.7万股，最新持股比例为8.98%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK1197","BK0183","BK1515","BK1191","BK0188","BK1521","600332","BK0012","BK0175","BK0097","BK0239","BK0096","00874","BK0028","BK0070","BK1606"],"gpt_icon":0},{"id":"2481765826","title":"白云山(00874)分公司获得药品补充申请批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2481765826","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481765826?lang=zh_cn&edition=full","pubTime":"2024-11-06 18:53","pubTimestamp":1730890406,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山 发布公告，近日，公司分公司广州白云山医药集团股份有限公司白云山制药总厂收到国家药品监督管理局签发的《药品补充申请批准通知书》。白云山制药总厂本次获得桑菊感冒颗粒《药品补充申请批准通知书》，完善了该药品的安全性信息，有利于提升该产品的市场竞争力。本次获得上述药品补充申请批准通知书，对公司当期业绩无重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0096","BK1606","BK1521","BK1197","BK0012","BK0183","BK1191","BK0196","BK0239","BK0070","BK0188","BK0175","00874","BK0028","BK0097","600332","BK1515"],"gpt_icon":0},{"id":"2481678471","title":"白云山最新公告：分公司获得药品补充申请批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2481678471","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481678471?lang=zh_cn&edition=full","pubTime":"2024-11-06 18:10","pubTimestamp":1730887840,"startTime":"0","endTime":"0","summary":"白云山公告，分公司白云山制药总厂收到国家药品监督管理局签发的《药品补充申请批准通知书》。药品通用名称为枸橼酸西地那非片。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600031446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK1197","BK0196","BK0175","BK0028","BK1515","BK0183","BK1606","BK1521","BK1191","BK0239","BK0070","BK0097","600332","BK0188","00874","BK0012"],"gpt_icon":0},{"id":"2481733776","title":"白云山：枸橼酸西地那非片获药品补充批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2481733776","media":"财通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481733776?lang=zh_cn&edition=full","pubTime":"2024-11-06 18:04","pubTimestamp":1730887440,"startTime":"0","endTime":"0","summary":"白云山公告，旗下白云山制药总厂获得国家药监局签发的枸橼酸西地那非片药品补充申请批准通知书，批准增加20mg规格并适用于治疗成人肺动脉高压，改善运动能力，延缓临床恶化。此外，桑菊感冒颗粒也获批变更说明书中安全性等内容。白云山制药总厂已在枸橼酸西地那非片研发项目上投入研发费用约776.94万元，在桑菊感冒颗粒研发项目上投入约10万元。本次补充申请的批准丰富了白云山的药品种类，有利于提升其市场竞争力，但对本公司当期业绩无重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106180510aba6061d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106180510aba6061d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0175","BK0239","BK0028","00874","BK0183","BK0097","BK0196","BK0070","BK0096","BK0188","BK0012","600332"],"gpt_icon":0},{"id":"2481520353","title":"白云山(00874.HK)头孢克(月兮)分散片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2481520353","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481520353?lang=zh_cn&edition=full","pubTime":"2024-11-05 17:50","pubTimestamp":1730800200,"startTime":"0","endTime":"0","summary":"白云山(00874.HK) 公布，分公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，头孢克(月兮)分散片已通过仿制药质量和疗效一致性评价。(sl/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-05 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200312162542031_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200312162542031_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1394294&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0012","600332","BK1521","BK0175","BK1515","BK0070","BK0239","BK1191","BK0188","BK1197","BK0196","BK0096","BK0097","BK1606","BK0183","00874","BK0028"],"gpt_icon":0},{"id":"2481852753","title":"白云山(00874)：头孢克肟分散片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2481852753","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481852753?lang=zh_cn&edition=full","pubTime":"2024-11-05 17:48","pubTimestamp":1730800091,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)发布公告，近日，广州白云山医药集团股份有限公司(以下简称“本公司”)分公司广州白云山医药集团股份有限公司白云山制药总厂(以下简称“白云山制药总厂”)收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，头孢克肟分散片已通过仿制药质量和疗效一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0175","BK1515","BK0012","BK0097","BK0188","BK1521","BK1191","BK1197","BK0096","BK0070","BK0196","BK0239","BK1606","600332","00874","BK0028"],"gpt_icon":0},{"id":"2481524956","title":"白云山：分公司头孢克肟分散片通过仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2481524956","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481524956?lang=zh_cn&edition=full","pubTime":"2024-11-05 17:20","pubTimestamp":1730798405,"startTime":"0","endTime":"0","summary":"白云山11月5日公告，近日，公司分公司广州白云山医药集团股份有限公司白云山制药总厂收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，头孢克肟分散片已通过仿制药质量和疗效一致性评价。截至公告日，白云山制药总厂针对该药品一致性评价已投入研发费用约892.97万元（未审计）。2023年度白云山制药总厂该药品的销售收入为5818万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105172005a2180b1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105172005a2180b1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0196","BK0096","600332","BK0097","BK0028","BK0175","BK0239","BK0070","BK0183","BK0188","BK0012"],"gpt_icon":0},{"id":"2481521428","title":"白云山最新公告：分公司药品通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2481521428","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481521428?lang=zh_cn&edition=full","pubTime":"2024-11-05 17:10","pubTimestamp":1730797806,"startTime":"0","endTime":"0","summary":"白云山公告，分公司白云山制药总厂收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，头孢克肟分散片已通过仿制药质量和疗效一致性评价。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500029639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["00874","BK1197","BK1521","BK0239","600332","BK0183","BK0070","BK0096","BK0097","BK0175","BK1606","BK1515","BK0196","BK0028","BK0188","BK1191","BK0012"],"gpt_icon":0},{"id":"2481524958","title":"白云山：子公司《药品生产许可证》变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2481524958","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481524958?lang=zh_cn&edition=full","pubTime":"2024-11-05 17:05","pubTimestamp":1730797542,"startTime":"0","endTime":"0","summary":"格隆汇11月5日丨白云山(600332.SH)公布，子公司广州白云山奇星药业有限公司(以下简称“奇星药业”)收到广东省药品监督管理局核准签发的《药品生产许可证》，同意奇星药业委托广州白云山中一药业有限公司(以下简称“中一药业”)生产蛇胆川贝散、喉康散和复方余甘子利咽含片，委托广州白云山医药集团股份有限公司白云山制药总厂(以下简称“白云山制药总厂”)生产健脾补血颗粒，本次奇星药业委托中一药业和白云山制药总厂生产药品，有利于本公司优化资源配置，继续保持稳定的生产能力，满足市场需求，本次获得《药品生产许可证》，对本公司当期业绩无重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105170549aba17351&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105170549aba17351&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0196","BK0096","BK0097","BK0183","BK0012","BK0239","600332","BK0175","BK0028","BK0188","BK0070"],"gpt_icon":0},{"id":"2481521312","title":"白云山(600332.SH)：头孢克肟分散片已通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2481521312","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481521312?lang=zh_cn&edition=full","pubTime":"2024-11-05 17:03","pubTimestamp":1730797437,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(600332.SH)发布公告，公司分公司广州白云山医药集团股份有限公司白云山制药总厂收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，头孢克肟分散片已通过仿制药质量和疗效一致性评价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206890.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK1191","BK0097","BK1515","BK0070","BK0175","BK1606","BK0028","BK0196","BK0239","BK0096","BK0188","BK1521","600332","00874","BK1197","BK0183"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2001-02-06","address":"广东省广州市荔湾区沙面北街45号","stockEarnings":[{"period":"1week","weight":-0.0269},{"period":"1month","weight":0.0227},{"period":"3month","weight":-0.0202},{"period":"6month","weight":-0.066},{"period":"1year","weight":0.0072},{"period":"ytd","weight":0.0392}],"companyName":"广州白云山医药集团股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"162579万元","compareEarnings":[{"period":"1week","weight":-0.0421},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.1595},{"period":"6month","weight":0.0523},{"period":"1year","weight":0.0882},{"period":"ytd","weight":0.1173}],"survey":"　　广州白云山医药集团股份有限公司主营业务中西成药、化学原料药、天然药物、生物医药、化学原料药中间体的研究开发、制造与销售;西药、中药和医疗器械的批发、零售和进出口业务;大健康产品的研发、生产与销售;医疗服务、健康管理、养生养老等健康产业投资。公司产品主要包括中成药、中药饮片、化学制剂、化学原料药、医药流通。集团是全国最大的制药企业集团之一。本集团及合营企业拥有国家级研发机构7家，国家级企业技术中心1家，博士后工作站2家。","serverTime":1732009778186,"listedPrice":9.8,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"白云山(600332)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供白云山(600332)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"白云山,600332,白云山股票,白云山股票老虎,白云山股票老虎国际,白云山行情,白云山股票行情,白云山股价,白云山股市,白云山股票价格,白云山股票交易,白云山股票购买,白云山股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"白云山(600332)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供白云山(600332)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}